Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

r, Houston, Texas
  • Abstract 7609, General Poster Session, Lung Cancer – Metastatic Track
  • Sunday, June 6, 2010, 8:00 a.m.-12:00 p.m., S Hall A2

  • Breast Cancer

    • Multivariate Analysis (MVA) of Progression-Free Survival (PFS) in 2 Phase 2b, Multinational, Double-Blind, Randomized, Placebo-Controlled Trials Evaluating Sorafenib Plus Standard Chemotherapy in Patients with HER-2 Negative Locally advanced or Metastatic Breast Cancer.
      • William John Gradishar, M.D., Northwestern University Feinberg School of Medicine, Chicago, Illinois
      • Abstract 1073, General Poster Session, Breast Cancer Track
      • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2
    • A Regional Subgroup Analysis of a Multinational, Double-Blind, Randomized, Placebo Controlled, Phase 2b Study Evaluating Sorafenib (SOR) with Paclitaxel (PAC) in Patients (pts) with Advanced Breast Cancer (BC).
      • Tarini Prasad Sahoo, M.D., Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal, India
      • Abstract 1114, General Poster Session, Breast Cancer Track
      • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2
    • Management of Hand-Foot Skin Reaction (HFSR)/Hand-Foot Syndrome (HFS) in SOLTI-0701: A Double-Blind, Randomized Phase 2b Study Comparing Sorafenib vs Placebo in Comb
      '/>"/>

    SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
    2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
    3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
    4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
    5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
    6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
    7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
    8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
    9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
    10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
    11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
    (Date:11/21/2014)... Why did Stephen Hawking become so famous? ... recognizable? Why have they become icons to rival film ... Ratcliffe seeks out the answers to those questions, and ... with science. In " Stephen Hawking Smoked My Socks ... Ratcliffe puts it plainly: , “It is profoundly ...
    (Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
    (Date:11/21/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results ... 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A have ... ended September 30, , Nine-months ended September ... 2014 , 2013 , 2014 , ... , 6,715 , 14,476 Gross profit , ...
    Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
    ... of siRNAs targeting , key ... cells. To identify genes involved in a given cellular process, , ... distinct response profiles such as ... Inc., who pioneered the field of High Content , ...
    ... , Up to 50X more activity and 350% greater ... Removes trace quantities of , DNA ... RNase-free and recombinant in , ... lower in RNase activity than bovine pancreas , ...
    ... ... fastest, easiest, and most consistent method for PAGE purification of small , ... which was designed for the visualization of small nucleic acids, the flashPAGE ... of RNA , and DNA. , ...
    Cached Biology Technology:Using Validated siRNAs in Functional Genomic Assays 2Using Validated siRNAs in Functional Genomic Assays 3TURBO DNase: Hyperactive, Salt Tolerant DNase 2TURBO DNase: Hyperactive, Salt Tolerant DNase 3TURBO DNase: Hyperactive, Salt Tolerant DNase 4TURBO DNase: Hyperactive, Salt Tolerant DNase 5Ultra-Fast Purification of Small Nucleic Acids 2Ultra-Fast Purification of Small Nucleic Acids 3Ultra-Fast Purification of Small Nucleic Acids 4Ultra-Fast Purification of Small Nucleic Acids 5
    (Date:11/4/2014)... (Nov. 4, 2014) – A majority of Madagascar,s 101 ... could have serious consequences for the rainforests they call ... the positive impacts lemurs can have on rainforest tree ... disappearance could have on the region,s rich biodiversity. , ... fruits eaten by lemurs. Lemurs in turn disperse ...
    (Date:11/3/2014)... DUBLIN , Nov. 3, 2014 Research ... report "Cell Therapy - Technologies, Markets and Companies" ... evaluates cell therapy technologies and methods, which have already started ... Hematopoietic stem cell transplantation is replacing the old fashioned bone ... described. Cell therapy is bound to become a part of ...
    (Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
    Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
    ... unusual symbiosis between tiny single-celled algae and highly specialized ... ecosystems, fertilizing the oceans by taking nitrogen from the ... organisms can use. Details of the symbiosis, ... , emerged from the investigation of a mysterious nitrogen-fixing ...
    ... development of new biocomposites based on the transformation ... for the construction sector. These innovative materials will ... BIocomposiTEs), a European Commission FP7 collaborative project co-participated ... (FI), EMPA (CH), EXERGY (UK), VERTECH (FR), ...
    ... pregnant makes a huge difference in the health of her ... ate before pregnancy might be important too. According to a ... Journal , what a group of female mice atebefore ... her offspring. These DNA alterations, called "epigenetic" changes, drastically affected ...
    Cached Biology News:Unusual symbiosis discovered in marine microorganisms 2Unusual symbiosis discovered in marine microorganisms 3Unusual symbiosis discovered in marine microorganisms 4TECNALIA leads research to develop new biocomposites based on wheat straw and recycled paper 2A mother’s nutrition--before pregnancy--may alter the function of her children’s genes 2
    ... Ready-to-use liquid controls for monitoring Aldolase ... & abnormal) with targeted manufacturing values ... 20 ± 3 IU/L. 30-day ... at 2-8 C. Level 1: 3 ...
    APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
    Recombinant Mouse sTNF RII/TNFRSF1B...
    Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
    Biology Products: